Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Immunoproliferative Disorders 2Immune System Diseases 2Cytokine Release Syndrome 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1Stomach Neoplasms 1Prostatic Neoplasms 1Neurotoxicity Syndromes 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hodgkin Disease 1Epstein-Barr Virus Infections 1Colorectal Neoplasms 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 63Androgen Antagonists 59Abiraterone Acetate 57apalutamide 55Radiosurgery 52darolutamide 48Radiotherapy 47Leuprolide 46abiraterone 45Docetaxel 42Pluvicto 32Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Radiation 30relugolix 28Surveys and Questionnaires 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24Gonadotropin-Releasing Hormone 23bicalutamide 22Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × AP 1903 reagent × 1 year × Clear all
NCT02744287 2026-02-23

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Regeneron Pharmaceuticals

Phase 1 Terminated
52 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡